Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
18 03 2022
Historique:
received: 26 01 2021
revised: 01 02 2022
accepted: 09 02 2022
pubmed: 23 2 2022
medline: 19 4 2022
entrez: 22 2 2022
Statut: ppublish

Résumé

National immunisation programmes require an adequate supply of vaccines to function properly but many countries, globally and in Europe, have reported vaccine shortages. A comprehensive view of vaccine shortages and stockouts in the EU/EEA is missing in the published literature. This study was conducted in the framework of the European Joint Action on Vaccination (EU-JAV). Twenty-eight countries, including 20 EU-JAV consortium member states and an additional 8 EU/EEA countries, were invited to participate in a survey aimed at collecting information on vaccine shortages and stock-outs experienced from 2016 to 2019, their main causes, actions taken, and other aspects of vaccine supply. Twenty-one countries completed the survey (response rate 75%), of which 19 reported at least one shortage/stock-out event. Overall, 115 events were reported, 28 of which led to a change in the national immunisation programme. The most frequently involved vaccines were DT- and dT-containing combination vaccines, hepatitis B, hepatitis A, and BCG vaccines. The median duration of shortages/stock-outs was five months (range <1 month-39 months). Interruption in supply and global shortage were the most frequently indicated causes. Only about half of countries reported having an immunization supply chain improvement plan. Similarly, only about half of countries had recommendations or procedures in place to address shortages/stockouts. The survey also identified the occurrence of shortages/stockouts of other biological products (e.g. diphtheria antitoxin in 12 countries). Public health strategies to assure a stable and adequate vaccine supply for immunization programmes require coordinated actions from all stakeholders, harmonized definitions, strengthening of reporting and monitoring systems, the presence of an immunization supply chain improvement plan in all countries, and procedures or recommendations in place regarding the use of alternative vaccines or vaccination schedules in case of shortages/stockouts.

Identifiants

pubmed: 35190211
pii: S0264-410X(22)00187-6
doi: 10.1016/j.vaccine.2022.02.041
pii:
doi:

Substances chimiques

BCG Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1987-1995

Informations de copyright

Copyright © 2022 Istituto Superiore di Sanità. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Antonietta Filia (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. Electronic address: antonietta.filia@iss.it.

Maria Cristina Rota (MC)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Adriano Grossi (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; Section of Hygiene and Preventive Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.

Domenico Martinelli (D)

Department of Medical and Surgical Sciences, University of Foggia, Italy; Department of Hygiene, Policlinico Riuniti University Hospital of Foggia, Italy.

Rosa Prato (R)

Department of Medical and Surgical Sciences, University of Foggia, Italy; Department of Hygiene, Policlinico Riuniti University Hospital of Foggia, Italy.

Giovanni Rezza (G)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Articles similaires

Glycogen Storage Disease Type II Humans Critical Pathways Europe
Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2
Bangladesh Humans COVID-19 COVID-19 Vaccines SARS-CoV-2
1.00
Humans Female Papillomavirus Vaccines Male Young Adult

Classifications MeSH